Akeso, Inc. ((HK:9926)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Akeso, Inc. is conducting a Phase III clinical study titled A Phase III, Randomized, Double-blinded, Multicenter Study of Cadonilimab (AK104) + Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma. The study aims to evaluate the effectiveness of combining AK104 and lenvatinib with TACE compared to TACE alone in treating patients with incurable, non-metastatic liver cancer.
The study tests an experimental treatment combining the drugs AK104 and lenvatinib with a procedure called transarterial chemoembolization (TACE). AK104 is administered intravenously, while lenvatinib is taken orally. TACE involves injecting chemotherapy and embolic agents into the hepatic artery.
This interventional study uses a randomized, parallel assignment model with quadruple masking to ensure unbiased results. The primary purpose is treatment, focusing on assessing the new combination’s efficacy against liver cancer.
The study began on April 15, 2024, with primary completion expected soon. The latest update was submitted on March 11, 2025, indicating ongoing recruitment and progress in the trial.
The outcome of this study could significantly impact Akeso’s market position and stock performance, especially if the combination treatment proves effective. It may also influence the competitive landscape in liver cancer treatment, affecting investor sentiment towards Akeso and its peers.
The study is currently ongoing, with more details available on the ClinicalTrials portal.